ArticleCancer cell international2024

Pitavastatin sensitizes the EGFR-TKI associated resistance in lung cancer by inhibiting YAP/AKT/BAD-BCL-2 pathway.

Jie Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.